NextCure, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $8.6 million, a decrease from the $11.5 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company reported a net loss of $46.4 million, compared to a loss of $44.1 million for the same period in the previous year. The reduction in quarterly losses is attributed to decreased operating expenses, which totaled $8.9 million for the quarter, down from $12.5 million in the prior year. The company’s accumulated deficit now stands at $426.5 million.
In terms of revenue, NextCure has not generated any product sales to date and does not anticipate doing so in the near future. The company’s cash and cash equivalents, along with marketable securities, totaled $29.1 million as of September 30, 2025, a significant decrease from $71.8 million at the end of 2024. This decline is primarily due to cash used in operating activities, which amounted to $42.0 million for the nine months ended September 30, 2025, compared to $33.8 million for the same period in 2024. The company has indicated that its current financial resources may not be sufficient to fund operations for the next year, raising concerns about its ability to continue as a going concern.
Strategically, NextCure has made significant moves, including a restructuring plan initiated in March 2024 to focus on its highest-value opportunities, specifically the clinical programs for SIM0505 and LNCB74. The company also entered into a License Agreement with Hainan Simcere Zaiming Pharmaceutical Co., Ltd. in June 2025, which included a $17 million payment for rights to develop and commercialize a clinical-stage antibody-drug conjugate. This agreement is expected to enhance NextCure's product pipeline and development capabilities.
Operationally, NextCure has seen a reduction in research and development expenses, which totaled $6.1 million for the third quarter of 2025, down from $8.8 million in the same quarter of 2024. This decrease is largely due to lower costs associated with deprioritized programs. The company is currently advancing its lead product candidates, SIM0505 and LNCB74, through clinical trials, with plans to provide proof of concept data for both in the first half of 2026. However, the company acknowledges that it will require substantial additional funding to support ongoing operations and clinical development efforts.
Looking ahead, NextCure's management has expressed the need to raise additional capital to extend its operational runway and continue advancing its clinical programs. The company is exploring various financing options, including public and private equity offerings, to secure the necessary funds. The success of these efforts will be critical in determining the future of its product development and overall business strategy.
About NextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical company developing innovative cancer therapies, primarily antibody-drug conjugates (ADCs). Its lead candidate, LNCB74, targets B7-H4, a tumor-associated protein, for cancers like breast and ovarian. The company also explores non-oncology programs, collaborates with LigaChem and Yale, and focuses on advancing targeted biologics through research, development, and strategic partnerships.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.